Canton Strategic Holdings (CNTN) Income towards Parent Company (2021 - 2026)
Canton Strategic Holdings (CNTN) posted Income towards Parent Company of -$47.3 million for Q1 2026, down 248.26% on a QoQ basis from -$13.6 million in Q4 2025, and down 1762.66% year-over-year from $2.8 million in Q1 2025.
Canton Strategic Holdings (CNTN) Income towards Parent Company (2021 - 2026) Analysis & Trends
Canton Strategic Holdings' Income towards Parent Company history runs 6 years deep, the most recent figure standing at -$47.3 million for Q1 2026.
- Quarterly Income towards Parent Company fell 1762.66% year-over-year to -$47.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$64.9 million (down 421.27% YoY) and the FY2025 annual result came in at -$42.9 million, down 252.06% from the prior year.
- Income towards Parent Company was -$47.3 million for Q1 2026 at Canton Strategic Holdings, down from -$13.6 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$188679.0 in Q4 2022 and bottomed at -$47.3 million in Q1 2026.
- A 5-year average of -$5.6 million and a median of -$2.3 million in 2023 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2022 — Income towards Parent Company surged 47.53% — and 2026, when it sank 1762.66%.
- Canton Strategic Holdings' Income towards Parent Company stood at -$188679.0 in 2022, then sank by 1211.1% to -$2.5 million in 2023, then plunged by 53.08% to -$3.8 million in 2024, then tumbled by 259.0% to -$13.6 million in 2025, then slumped by 248.26% to -$47.3 million in 2026.
- Business Quant data shows CNTN's Income towards Parent Company at -$47.3 million in Q1 2026, -$13.6 million in Q4 2025, and -$2.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn |
| 10 | Canton Strategic Holdings | 430.99 Mn | 430.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.34 Mn |
| Dec 31, 2025 | -13.59 Mn |
| Sep 30, 2025 | -2.10 Mn |
| Jun 30, 2025 | -1.86 Mn |
| Mar 31, 2025 | -2.54 Mn |
| Dec 31, 2024 | -3.79 Mn |
| Sep 30, 2024 | -3.80 Mn |
| Jun 30, 2024 | -2.33 Mn |
| Mar 31, 2024 | -2.26 Mn |
| Dec 31, 2023 | -2.47 Mn |
| Sep 30, 2023 | -1.82 Mn |
| Jun 30, 2023 | -2.34 Mn |
| Mar 31, 2023 | -2.69 Mn |
| Dec 31, 2022 | -188,679.00 |
| Sep 30, 2022 | -2.13 Mn |
| Jun 30, 2022 | -1.64 Mn |
| Mar 31, 2022 | -2.95 Mn |
| Dec 31, 2021 | -359,593.00 |
| Sep 30, 2021 | -777,113.00 |
| Jun 30, 2021 | -1.29 Mn |